• LAST PRICE
    0.9156
  • TODAY'S CHANGE (%)
    Trending Up0.0255 (2.8648%)
  • Bid / Lots
    0.9156/ 18
  • Ask / Lots
    0.9200/ 68
  • Open / Previous Close
    0.9044 / 0.8901
  • Day Range
    Low 0.9002
    High 0.9200
  • 52 Week Range
    Low 0.8600
    High 4.5600
  • Volume
    79,525
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 0.8901
TimeVolumeCTXR
09:32 ET60380.9075
09:34 ET31590.91
09:36 ET33600.9146
09:38 ET57530.9146
09:39 ET229050.92
09:41 ET6480.9191
09:43 ET250710.92
09:45 ET8520.915
09:48 ET72410.9156
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCTXR
Citius Pharmaceuticals Inc
131.1M
-4.7x
---
United StatesGMDA
Gamida Cell Ltd
132.0M
-1.6x
---
United StatesSVRA
Savara Inc
130.0M
-3.7x
---
United StatesGRPH
Graphite Bio Inc
132.2M
-2.0x
---
United StatesABOS
Acumen Pharmaceuticals Inc
128.8M
-1.2x
---
United StatesSPPI
Spectrum Pharmaceuticals Inc
134.4M
-0.8x
---
As of 2022-05-17

Company Information

Citius Pharmaceuticals Inc. specialty pharmaceutical company. The Company develops and commercializes critical care products with a focus on anti-infective products in adjunct cancer care, prescription products and mesenchymal stem cell therapy. It has five products: Mino-Lok, Mino-Wrap, Halo-Lido, NoveCite and I/ONTAK. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. Halo-Lido is a corticosteroid-lidocaine topical formulation, which is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. NoveCite is a mesenchymal stem cell therapy for the treatment of ARDS. I/ONTAK is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma.

Contact Information

Headquarters
11 Commerce Dr Fl 1CRANFORD, NJ, United States 07016-3501
Phone
908-967-6677
Fax
---

Executives

Executive Chairman of the Board, Chief Executive Officer, Company Secretary
Leonard Mazur
Executive Vice Chairman of the Board
Myron Holubiak
Chief Financial Officer, Chief Business Officer
Jaime Bartushak
Chief Medical Officer, Executive Vice President
Myron Czuczman
Vice President - Corporate Communications and Investor Relations
Ilanit Allen

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$131.1M
Revenue (TTM)
$0.00
Shares Outstanding
146.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.65
EPS
$-0.19
Book Value
$0.91
P/E Ratio
-4.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.